Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged >=35 years: a randomized controlled trial

Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis

(2014) Philippe Lehert et al.   Reproductive Biology and Endocrinology

Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study

(2013) T. E. Konig et al.   HUMAN REPRODUCTION

Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH

(2013) Vuong Thi Ngoc Lan et al.   REPRODUCTIVE BIOMEDICINE ONLINE

The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis

(2012) Micah J. Hill et al.   FERTILITY AND STERILITY

ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria

(2011) A. P. Ferraretti et al.   HUMAN REPRODUCTION

Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective

(2011) Peng Cheang Wong et al.   REPRODUCTIVE BIOMEDICINE ONLINE

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

(2010) Ernesto Bosch et al.   FERTILITY AND STERILITY

Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study

(2009) R Matorras et al.   REPRODUCTIVE BIOMEDICINE ONLINE